Anthony Ball Mendon, MA 01756 – (508) 341-3715 – nora.mdr@gmail.com

Anthony Ball, NRCM, MSHS

Summary A proven, highly motivated professional with skills leading multi-disciplinary teams, directing operations, research & development, regulatory affairs, reporting to stakeholders, obtaining capital and funding, negotiations, & contracts.

Objectives To lead change and promote inclusion, quality, efficiency, development, cost-savings, & empower teams. To apply best practices and current thinking for the promotion of excellence in quality, satisfaction, and stakeholder value creation.

Competencies

- Leadership, Organizational Behavior & Change Management
- Business Management & Development
- Technical Expertise & Research
- Capital and Fund Raising
- Teamwork, Multidisciplinary Team Building & Management, Coaching & Conflict Resolution
- Laboratory Operations & Management
- Science & Engineering (e.g. Photobiology, Optoelectronics, Optics, Molecular Biology, Microbial Genetics, Biomedical Engineering, Antimicrobial Discovery, Polymers, Nanomedicine, Vaccines, Medical Devices, Microbiology) (see Google Scholar)
- Clinical Sciences, (e.g. Design, Review, Management, Filings)
- Communications
- Strategic Planning & Development
- Negotiations
- Time Management, Project Management Program Management
- Quality Systems
- Efficiency & Organization
- Research & Development
- Proposals & Grant Writing
- Data Analysis, Reporting & Communication
- Intellectual Property
- Global Regulatory Affairs and Compliance
- Business Operations
- Client Relations and Customer Experience Improvement
- Contract & Vendor Management

Education

Northeastern University, College of Arts and Sciences, Bachelor of Science, *Biology & History*

Northeastern University, Graduate School of Arts and Sciences, Doctorate of Philosophy, *Bacteriology* (ABD)

George Washington University, School of Medicine and Health Sciences, Master of Science Health Science, *Regulatory Affairs*

Experience

VP of Compliance, Co-Founder, BioCellR8 LLC, Charlton MA 01507 August 2024 to Present

• Serving a mission to deliver key medicinal and therapeutic products into foreign markets where access to safe and effective medicines is needed through the establishment of a wholesale distribution and export-import enterprise.
• Ensure all regulated commerce is compliant with state, local, national laws.
• Develop and implement operational protocols in accordance with the FDA Export Reform and Enhancement Act of 1996.
• Establish and maintain the QMS and ensure transparent, accurate, and on-time record keeping and notification requirements.
• Leverage national laws incentivizing international commerce to facilitate foreign investment, fast-track licensing and registration, and promote a business-friendly environment for qualifying investments across various therapeutic and medicinal segments.

Anthony Ball Mendon, MA 01756 – (508) 341-3715 – nora.mdr@gmail.com

Chief Executive Officer, Owner Gliese 623B Consulting LLC, Mendon, MA 01756 October 2014 to December 2023

• Spearheaded exponential growth achieving annual revenue of over $300,000 by the end of year three.
• Secured $13 million in financing and capital to support Gliese-sponsored research initiatives.
• Directed and guided a mission statement, advancing human health and wellness, through guided discovery.
• Established dozens of research partnerships both domestically and internationally.
• Submitted $18 million USD in scored research proposals to the NIH, DOD, and EU focusing on biofilms, infection control, antimicrobials, and photobiology.
• Established and managed extensive and intricate business relationships among capital investment partners, research institutions, third-party collaborators, and vendors.

Chief Scientific Officer, Co-Founder & Voting Member - Board of Directors
GAMA Therapeutics LLC (Gliese 623B LLC & Remphos Technologies LLC spin-out), Worcester, MA 01605 - January 2018 to June 2020

• Led research activities for US Army contract W81XWH-18-C-0003 (US Army Medical Research Acquisition Activity) and provided monthly reports and a final report to the program office using eBRAP.
• Specified & directed the design, prototyping, testing, and manufacture of several unique optoelectrical medical devices for the US Army capable of re-sterilizing medical connections placed on the battlefield.
• Established & operated a BSL-2 microbiology laboratory and electrical engineering workshop.
• Developed and implemented a regulatory & quality system (including SOPs) in compliance with OSHA and other state and federal regulations describing laboratory conduct.
• Managed a 10-person team comprised of electrical engineers, physicists, & biologists, an attorney and several contractors.
• Prepared business materials, such as plans & pitches, market analysis & literature searches.
• Developed & submitted 16 unique research grants to the NIH, DOD, EU, and private funds using original data ($1.6 million USD awarded) over 24 months and raised an additional half million USD in private capital using GRANTS.GOV and other databases.
• Filed provisional patent, *SYSTEM AND METHOD TO ERADICATE A MAJORITY OF DISEASE-CAUSING BACTERIA AND PRODUCE AVIRULENT PHENOTYPE BACTERIA SUSCEPTIBLE TO ANTIMICROBIAL AGENTS USING A LIGHT DOSE REGIMENT* (# 62/864,762).
• Published a review article on clinical biofilms (PMID: 29618576) and inactivation strategies for Covid-19 using ultraviolet irradiation (PMID: 32855026).
•Received the Marie Skłodowska-Curie Individual Fellowships (H2020-MSCA-IF-2018) recipient (# 843116), Army Tech Search 3.0 award (Frederick, MD), and was finalist to WPI Venture Forum, and semi-finalist to START MassVentures, while promoting GAMA technology.

Principal Investigator Gliese 623B Consulting LLC/University of Massachusetts Lowell, M2D2, Lowell, MA – December 2015 to February 2017

• Scientific liaison to Gliese research sponsors and the Board of Directors, presenting research findings to stakeholders and capital partners.
• Secured $5 million in capital through fundraising efforts.
• Developed and implemented an approved research plan for University of Massachusetts Lowell, taking charge of scientific conduct, financing, management, training, and safety requirements of a BSL-2 microbiology/bioanalytical laboratory operating under all state and federal regulations.

• Patented two inventions titled *SYSTEM AND METHOD FOR HEALING AND/OR DISINFECTING WOUNDS AND BURNS* (# US20180093107A1) and *SYSTEM AND METHOD FOR STERILIZATION USING ULTRAVIOLET RADIATION* (US20180369560A1).
• Published two original research articles on photosensitization using conjugated drug-efflux pump inhibitors against infectious microbes including MRSA (PMID: 29519734 & PMID: 28799332).
• Participated in university-led public relation activities at the University and supported the training and education of the students & received a Massachusetts Life Sciences Center student award.

Chief Scientific Officer & Principal Microbiologist, Co-Founder, GROW-RI (Gliese 623B LLC spin-out), Newport, RI - April 2020 to April 2022
• Assembled a team of accomplished business leaders to develop and execute the vision of democratizing high-tech computer control and robotic automation systems for small-scale indoor farmers.
• Launched a lean start-up with limited initial funding, resulting in the establishment of multiple product lines of SCADA systems, data terminals, and chemical barrier coatings.
• Negotiated and finalized several licensing agreements with third-party OEMs.
• Developed proposals and conducted comprehensive market research to identify target markets and opportunities.
• Established and managed a remote sales force, implementing a training program to ensure sales effectiveness and product knowledge.
• Generated numerous engineering concepts in the field of agriculture, leading to the development of detailed design specifications.
• Implemented a media relations program to effectively introduce high-technology concepts to the market.

FDA Study Director, Microbiology Toxikon Corporation, Bedford, MA April 2010 to October 2014
• Led all special research studies in the department of microbiology, ensuring compliance with federal and regulatory requirements such as 21 CFR Part 58 (GLP), ISO 17025, and ASTM, USP standards.
• Applied expertise in microbiology, method development and validation.
• Effectively managed and trained laboratory staff.
• Created and maintained quality compliance system documentation, including SOPs and FDA 510(k) compliant study protocols.
• Convinced executive leadership to approve a revised revenue plan, increasing profits tens of millions of dollars over three years.
• Served as the study director and managed the microbiology validation efforts on over seventy product registrations (510K pre-market approvals & preclinical IDEs).
• Provided expert insight and represented the corporate brand at several research conferences, symposia, and the like and produced several research publications (PMID 22242675 and a CABI book chapter)
• Provided subject matter expertise (SME) for clientele before regulatory authorities such as the Food and Drug Administration.